Pharmaceutical Product Monograph: Ampicillin & Flucloxacillin Capsules
In the pharmaceutical industry, the Ampicillin and Flucloxacillin combination (often referred to by the brand name Magnapen or as Co-fluampicil) is a specialized Dual-Penicillin therapy. As a pharmacist and manufacturer, I view this as a “Total-Spectrum Solution” for acute infections where the specific bacteria have not yet been identified.
At your WHO-GMP facility in Mumbai, this combination is a high-demand SKU for General Surgery, Dermatology, and Acute Care portfolios, particularly in B2B markets that prioritize hospital-grade empirical treatments.
Therapeutic Profile: Primary Indications
This combination is taken to treat infections where both Gram-positive and Gram-negative bacteria are suspected, especially those involving resistant Staphylococci.
| Indication | Clinical Context | Technical Rationale |
| Severe Skin & Soft Tissue | Cellulitis / Abscesses | Gold Standard: Flucloxacillin kills resistant Staph, while Ampicillin targets Streptococci. |
| Post-Operative Prophylaxis | Surgical Wounds | Used to prevent infections from skin-dwelling bacteria following surgery. |
| Respiratory Tract | Pneumonia / Bronchitis | Provides broad coverage for common respiratory pathogens, including those that produce penicillinase. |
| Bone & Joint Infections | Osteomyelitis | Effective for deep-seated infections where mixed bacterial populations are common. |
| Septicemia | Blood Infections | Often used as an initial treatment while waiting for blood culture results. |
Mechanism: The “Synergistic Wall Breach”
This product works by sabotaging the bacterial cell wall through two distinct pharmacological pathways:
Ampicillin (The Broad-Spectrum Spear): It is an aminopenicillin that targets a wide range of bacteria. However, it is easily destroyed by Beta-lactamase enzymes.
Flucloxacillin (The Enzyme Shield): Flucloxacillin is a Penicillinase-resistant penicillin. Its bulky chemical structure prevents bacterial enzymes from breaking its ring, and it effectively kills “Staph” that would survive Ampicillin alone.
The Result: By combining them, you ensure that the infection is treated regardless of whether the bacteria produce resistance enzymes or are Gram-negative.
Bactericidal Lysis: They bind to Penicillin-Binding Proteins (PBPs), causing the bacterial cell to burst and die.
The Pharmacist’s “Technical Warning”
The “Empty Stomach” Rule: For maximum bioavailability, these capsules must be taken 30–60 minutes before food. Food significantly interferes with the absorption of Flucloxacillin.
The “Mono” Rash: Avoid use in patients with Infectious Mononucleosis (Glandular Fever). The Ampicillin component will likely cause a bright red, non-allergic skin rash.
Hepatic Monitoring: Flucloxacillin is technically associated with a rare risk of Cholestatic Jaundice. It should be used with caution in the elderly or those with pre-existing liver issues.
Penicillin Allergy: A history of Anaphylaxis with any penicillin is a strict contraindication for this combination.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Stability” USP: Flucloxacillin is highly sensitive to moisture (hygroscopic). On your digital marketplace, highlight your Alu-Alu Blistering. This is a technical requirement for B2B export to “Zone IVb” (tropical) regions to ensure the capsules remain potent and do not soften.
The “Hospital Grade” Market: Position this combination as a “Primary Hospital Choice” for international tenders. It is a staple in the UK and Middle Eastern markets for post-surgical recovery.
Dossier Support: we provide full WHO-standard CTD/eCTD Dossiers for Ampicillin + Flucloxacillin (250 mg + 250 mg) to support your registration in international B2B markets.